Table 1.
Patient characteristics
| All patients | GPS score | |||||
|---|---|---|---|---|---|---|
| n = 214 | 0 (n = 141) | 1 (n = 43) | 2 (n = 30) | P‐value | ||
| Age | <65 years/≥65 years | 62/152 | 44/97 | 10/33 | 8/22 | 0.57 |
| Sex | Male/Female | 83/131 | 51/90 | 18/25 | 14/16 | 0.50 |
| Stage | I/II/III/IV | 23/5/26/160 | 16/4/21/100 | 5/0/3/35 | 2/1/2/25 | 0.51 |
| Smoking status | Ever/never | 76/138 | 45/96 | 17/26 | 14/16 | 0.25 |
| ECOG‐PS | 0–1/2/3/4 | 168/33/8/5 | 126/12/2/1 | 30/10/2/1 | 12/11/4/3 | <0.01 |
| Histology | Ad/non‐Ad | 212/2 | 140/1 | 43/0 | 29/1 | 0.30 |
| EGFR mutation | Ex19del/L858R/other | 107/98/9 | 76/61/4 | 19/21/3 | 12/16/2 | 0.43 |
| T790M mutation | Positive/negative or unknown | 17/197 | 13/128 | 4/39 | 0/30 | 0.22 |
| EGFR‐TKI | Gefitinib/erlotinib/afatinib | 144/33/37 | 92/20/29 | 27/10/6 | 25/3/2 | 0.14 |
| Line of EGFR‐TKI | 1/2/≥3 | 163/41/10 | 109/26/6 | 31/8/4 | 23/7/0 | 0.42 |
Ad, adenocarcinoma; ECOG‐PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; GPS, Glasgow prognostic score; TKI, tyrosine kinase inhibitor.